Open Access

Protective effect of sacubitril/valsartan in patients with acute myocardial infarction: A meta‑analysis

  • Authors:
    • Shanshan Liu
    • Bi Yin
    • Bo Wu
    • Zhixing Fan
  • View Affiliations

  • Published online on: April 21, 2022     https://doi.org/10.3892/etm.2022.11333
  • Article Number: 406
  • Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

To evaluate the effects and safety of sacubitril/valsartan in patients with acute myocardial infarction (AMI), a total of four databases, including PubMed, Cochrane Library, Embase and Web of Science, and the ClinicalTrials.gov website were searched. Using a combination of medical subject headings and entry terms, the final search was performed in July 2021. A manual search of cross‑references from the original articles was also conducted. The meta‑analysis was subsequently performed with Revman 5.3 software and a total of four studies comprising 586 patients were included. The results disclosed a significant reduction in major adverse cardiovascular and cerebrovascular events (MACCEs) [odds ratio (OR), 0.47; 95% confidence interval (CI), 0.30‑0.73; P=0.0007], readmission (OR, 0.45; 95% CI, 0.29‑0.71; P=0.0006), incidence of acute heart failure (AHF) (OR, 0.45; 95% CI, 0.28‑0.71; P=0.0007) and N‑terminal pro B‑type natriuretic peptide [standardized mean difference (SMD), ‑0.88; 95% CI, ‑1.55‑(‑0.21); P=0.01] in the sacubitril/valsartan group compared with that in the control group, and a random effects model was used to pool these data. No significant differences were identified in the incidence of hypotension (OR, 2.91; 95% CI, 0.55‑15.51; P=0.21), adverse events (OR, 2.19; 95% CI, 0.42‑11.37; P=0.35), left ventricular ejection fraction (mean difference, 1.96; 95% CI, ‑0.84‑4.76; P=0.17) or soluble suppression of tumorigenesis‑2 (SMD, ‑0.45; 95% CI, ‑1.62‑0.71; P=0.45) according to the random effects model.In conclusion, the present meta‑analysis revealed that sacubitril/valsartan was able to effectively reduce the incidence of MACCEs, readmission and AHF in patients with AMI after revascularization without any obvious adverse events.

Related Articles

Journal Cover

June-2022
Volume 23 Issue 6

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Liu S, Yin B, Wu B and Fan Z: Protective effect of sacubitril/valsartan in patients with acute myocardial infarction: A meta‑analysis. Exp Ther Med 23: 406, 2022
APA
Liu, S., Yin, B., Wu, B., & Fan, Z. (2022). Protective effect of sacubitril/valsartan in patients with acute myocardial infarction: A meta‑analysis. Experimental and Therapeutic Medicine, 23, 406. https://doi.org/10.3892/etm.2022.11333
MLA
Liu, S., Yin, B., Wu, B., Fan, Z."Protective effect of sacubitril/valsartan in patients with acute myocardial infarction: A meta‑analysis". Experimental and Therapeutic Medicine 23.6 (2022): 406.
Chicago
Liu, S., Yin, B., Wu, B., Fan, Z."Protective effect of sacubitril/valsartan in patients with acute myocardial infarction: A meta‑analysis". Experimental and Therapeutic Medicine 23, no. 6 (2022): 406. https://doi.org/10.3892/etm.2022.11333